We reported a female presented with an initial diagnosis of metastatic axillary lymph‐node carcinoma that comprehensive assessments revealed a definitive diagnosis of high‐grade serous ovarian carcinoma as the primary tumor.
We reported a female with endometrial adenocarcinoma who was evaluated with whole‐body bone scan for new‐onset bone pains 6 months after completion of treatment.
A 26-year-old woman at 30 weeks of gestation referred due to PPROM. From
second day after CS, the patients fever increased and Doppler sonography
shows low fluid and hematoma in the uterus. Wound debridement conducted
and during laparotomy the adhesions were released. The Wright-Coombs 2ME
showed infection to brucellosis.
Introduction: The incidence of vulvar cancer is nearly 5% of all gynecologic malignancies and almost 95% of vulvar cancers are squamous cell carcinoma (SCC). Recurrence is possible in 4 ways: local, regional, pelvic, and distant. In a cohort of 391 patients with vulvar SCC, distant metastasis was reported 5% .The common sites of distant metastasis are pelvic nodes, lung, and liver. Both skin and bone metastasis are rare in vulvar SCC. Case Presentation: The current report presented a 58-year-old female with the diagnosis of vulvar SCC. She was the 11th cutaneous metastasis, 13th bone metastasis, and the 1st case with simultaneous bone and skin metastasis reported in the last 60 years. Conclusions: It is necessary to consider any lesion on the vulve, especially in menopause females, and it should be the low threshold for biopsy to avoid delay in detection. After completion of selective treatment, the exact follow-up should be considered to discover metastases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.